全國服務咨詢熱線：
18438616290
18438616290
產品分類
Product Category詳細介紹
| 品牌 | absin | CAS | 164650-44-6 |
|---|---|---|---|
| 分子式 | C18H22F2N4O | 純度 | 98% |
| 分子量 | 348.34 | 貨號 | abs47027999 |
| 規(guī)格 | 10mg | 供貨周期 | 現貨 |
| 主要用途 | is a novel triazole antifungal drug | 應用領域 | 化工,生物產業(yè),農林牧漁,制藥/生物制藥,綜合 |
Efinaconazole 164650-44-6
| 產品描述 | |
| 描述 | Efinaconazole(KP-103) is a novel triazole antifungal drug currently under development as a topical treatment for onychomycosis. |
| 純度 | 98% |
| 儲存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 可溶性/溶解性 | 10 mM in DMSO |
| 生物活性 | |
| 靶點 | 14 alpha-demethylase |
| In vitro(體外研究) | In in vitro antifungal susceptibility tests, efinaconazole shows lower minimum inhibitory concentration (MIC) than terbinafine, ciclopirox, itraconazole and amorolfine. |
| In vivo(體內研究) | Efinaconazole is a topical antifungal, so it has relatively low systemic accumulation. The plasma half-life after 10 days of administration is 29.9 h. It has high plasma protein-binding affinity from 95.8 to 96.5%; primarily to albumin, a1-acid glycoprotein and γ-globulin. Efinaconazole is metabolized extensively through oxidative and reductive processes resulting in a sole H3 metabolite. It may also undergo glucuronidation. Efinaconazole does not have significant interactions with CYP450 enzymes in the liver. CYP2C8, CYP2C9, CYP2C19 and CYP3A4 are inhibited by efinaconazole at concentrations higher than the systemic concentrations achieved clinically. |
| 研究領域 | |
| 研究領域 | MetabolismTypes of disease Drug DiscoverySmall Molecule DrugLead Compound Discovery |
產品咨詢
地址：上海市浦東新區(qū)新浩路58號申江科創(chuàng)園18棟
郵箱：
傳真：